Impaired vasodilator responses to atrial natriuretic peptide in essential hypertension

European Journal of Clinical Investigation

Volumn 33, Issue 7, 2003, Pages 567-573

  Bulut, D ^a   Potthast, R ^b   Hanefeld, C ^a   Schulz, T ^a   Kuhn, M ^b   Mugge A ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Atrial natriuretic peptide; Essential hypertension; GC A receptor; Vasodilator response

Indexed keywords

ACETYLCHOLINE; ATRIAL NATRIURETIC FACTOR; CELL SURFACE RECEPTOR; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLYL CYCLASE TYPE A; NITRIC OXIDE; NITROPRUSSIDE SODIUM; ORCIPRENALINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELETION MUTANT; DIURESIS; ESSENTIAL HYPERTENSION; FOREARM BLOOD FLOW; GENE; GUANYLYL CYCLASE A GENE; HUMAN; INFUSION; JAPAN; MALE; NATRIURESIS; PATHOGENESIS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RISK FACTOR; STRAIN GAUGE VENOUS PLETHYSMOGRAPHY; VASODILATATION;

ATRIAL NATRIURETIC FACTOR; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BODY MASS INDEX; FOREARM; GENE DELETION; GUANYLATE CYCLASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MUTATION; VASODILATOR AGENTS;

EID: 0038466277     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01188.x     Document Type: Article

References (32)

1. DeBold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of the myocardial extract in rats. Life Sci 1981;28:89-94.
2. Gower WR, Chiou S, Skolnick KA, Vesely DL. Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites. Peptides 1994;15:861-7.
3. Chinkers M, Garbers DL, Chang MS, Lowe DG, Chin H, Goeddel DV et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989;338:78-83.
4. Fuller F, Parter JG, Arfsten AE, Miller J, Schilling JW, Searborough RM et al. Atrial natriuretic peptide clearance receptor: complete sequence and functional expression of cDNA clones. J Biol Chem 1988;263:9395-401.
5. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995;378:65-8.
6. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad USA 1997;94:14730-5.
7. Lopez MJ, Garbers DL, Kuhn M. The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signalling. J Biol Chem 1997;272:23064-8.
8. John SWM, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995;267:679-81.
9. Melo LG, Veress AT, Ackermann U, Pang SC, Flynn TG, Sonnenberg H. Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Regul Pept 1999;79:109-15.
10. Rutledge DR, Sun Y, Ross EA. Polymorphism within the atrial natriuretic peptide gene in EH. J Hypertens 1995;13:953-5.
11. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K. Functional deletion mutation of the 5′flanking region of type A human natriuretic peptide receptor gene and its association with EH and left ventricular hypertrophy in the Japanese. Circ Res 2000;86:841-5.
12. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-23.
13. De Palo EF, Woloszczuk W, Meneghetti M, De Palo CB, Nielsen HB, Secher NH. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000;46:843-7.
14. Kuhn M, Raida M, Adermann K, Schulz-Knappe P, Gerzer R, Heim JM et al. The circulating bioactive form of human guanylin is a high molecular weight peptide (10.3 kDa). FEBS Lett 1993;318:205-9.
15. Aoshima T, Sekido Y, Miyazaki T, Kajita M, Mimura S, Watanabe K et al. Rapid detection of deletion mutations in inherited metabolic diseases by melting curve analysis with LightCycler. Clin Chem 2000;46:119-22.
16. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996;93:13176-81.
17. Sugawara A, Nakao K, Sakamoto M, Morii N, Yamada T, Itoh H et al. Plasma concentration of atrial natriuretic polypeptide in EH. Lancet 1985;II:1426-7.
18. Sagnella GA, Markandu ND, Shore AC, MacGregor GA. Raised circulating levels of atrial natriuretic peptides in EH. Lancet 1986;I:179-81.
19. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S et al. Human brain natriuretic polypeptide, a novel cardiac hormone. Lancet 1990;335:801-2.
20. Ganau A, Devereux RB, Atlas SA, Pecker M, Roman MJ, Vargiu P et al. Plasma atrial natriuretic factor in EH, relation to cardiac size, function and systemic haemodynamics. J Am Coll Cardiol 1989;14:715-24.
21. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y et al. Relationship between left ventricular geometry and natriuretic peptide levels in EH. Hypertension 1996;28:22-30.
22. Bettencourt P, Ferreira A, Sousa T, Ribeiro L, Brandao F, Polonia J et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol 1999;69:169-77.
23. Suzuki M, Yamamoto K, Watanabe S, Iwata T, Hamada M, Hiwada K. Association between elevated brain natriuretic peptide level and the development of left ventricular hypertrophy in patients with hypertension. Am J Med 2000;108:627-33.
24. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: blunted response in EH. Circulation 1990;81:1762-7.
25. Panza JA, Quyyumi AA, Brush JE, Epsetin SE. Abnormal endothelium dependent vascular relaxation in patients with EH. N Engl J Med 1990;323:22-7.
26. Panza JA, Casino PR, Kilcoynr CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with EH. Circulation 1993;87:1468-74.
27. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-33.
28. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon RO, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with EH. Circulation 1998;97:851-6.
29. Perricone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
30. Bolli P, Müller FB, Linder L, Raine AEG, Resink TJ, Erne P et al. Greater vasodilator responsiveness to atrial natriuretic peptide in low-renin essential hypertensives. J Hypertens 1987;5 (Suppl. 5):S 55-8.
31. Cao L, Wu J, Gardner DG. Atrial natriuretic peptide suppresses the transcription of its guanylyl cyclase-linked receptor. J Biol Chem 1995;270:24891-7.
32. Lincoln TM, Dey N, Sellak H. cGMP-dependent protein kinase signalling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001;91:1421-30.